News

As part of the deal, Vertex will have worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, including P-1037 and P-1055. Parion will receive an upfront payment

About the trial The trial reached its targeted enrollment of nine patients, who are two years of age or greater but less than 12 years of age, with

HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, and cannot be accounted for by another medical physical or psychiatric

This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic

Adapt has partnerd with biopharmaceutical firm Lightlake Therapeutics to develop treatments for opioid overdose. In December, Lightlake has agreed to license its opioid overdose reversal treatment to a

AR-12 is an orally-available small molecule. Data reported earlier shows that the mechanism of action of the molecule may include induction of host cell autophagy and inhibition of

The Enhanze platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in

Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved the brand name Galafold. Amicus Therapeutics chairman and CEO John Crowley said:

The VX-745 is an oral brain penetrant, which is highly selective and a potent inhibitor of the alpha isoform of the protein enzyme p38 mitogen activated protein kinase